← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Accelerated approvalNew therapyMedullary thyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Sep 27, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults and children ages 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy.

LAMPGEN ANALYSIS

Why it matters

Established targeted RET inhibition as an approved option for a molecularly defined medullary thyroid cancer population.

What research teams should watch

Distinguish a RET mutation from a fusion and coordinate age-appropriate testing and longitudinal monitoring.

PRIMARY RECORDS

Sources